Progress of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of operable non-small cell lung cancer
10.3760/cma.j.cn115355-20220610-00362
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂治疗可手术非小细胞肺癌的研究进展
- Author:
Jingying NONG
1
;
Ruotian WANG
;
Shuyang YAO
;
Xiaoxue LI
;
Yi ZHANG
Author Information
1. 首都医科大学宣武医院胸外科 国家老年疾病临床医学研究中心肿瘤诊疗中心，北京 100053
- Keywords:
Carcinoma, non-small-cell lung;
Receptor, epidermal growth factor;
Tyrosine kinase inhibitors;
Molecular targeted therapy;
Neoadjuvant therapy
- From:
Cancer Research and Clinic
2023;35(6):476-480
- CountryChina
- Language:Chinese
-
Abstract:
Patients with operable non-small cell lung cancer (NSCLC) receiving neoadjuvant or adjuvant chemotherapy have a very limited improvement in 5-year survival rate. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have made a breakthrough in the treatment of EGFR-mutant advanced NSCLC, which shed light for the exploration of perioperative targeted therapy in NSCLC patients. Significant progress has been made in the research of targeted therapy of the first and third generation EGFR-TKI in perioperative patients. The availability of novel potent and less toxic targeted therapy has brought new treatments for the operable NSCLC. This article reviews the progress and existing problems of adjuvant and neoadjuvant targeted therapy in NSCLC harboring EGFR mutation.
